Totally agree. The early trial results look very promising, especially at the 25 mg and 50 mg doses which I think is what they're testing moving forward. The 50 mg group had a 70% rate for PSA halving (or better) and 40% of them saw their PSA fall over 90%. That is obviously a very small sample size - but it's a success rate that is about twice as good as Cabazitaxel and also better than Lutetium-177, if those results are repeated.
So that's positive news, probably explains why the Marsden people were optimistic, and with good resson. You're in very good hands, Phil.
We have a consultation for my father next Friday with his oncologist to discuss trials. Do you happen to know if they're still accepting patients for this trial at the Marsden? We're looking at this one and the PAnTHA one at UCLH for Actinium-225 - given Lutetium-177 didn't make a dent in my father's disease, this trial could be a better option if it's still possible to get him into it. Weirdly there's nothing online about this trial coming to the UK, it's all about the US. I might enquire with the oncologist next week.